Topical ocular antibiotics induce bacterial resistance at extraocular sites

British Journal of Ophthalmology

Volumn 89, Issue 9, 2005, Pages 1097-1099

  Gaynor, B D ^a,b   Chidambaram, J D ^a   Cevallos, V ^a   Miao, Y ^a   Miller, K ^a   Jha, H C ^c   Bhatta, R C ^c   Chaudhary, J S P ^c   Holm, S Osaki ^a   Whitcher, J P ^a   Holbrook, K A ^d   Fry, A M ^e   Lietman, T M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Geta Eye Hospital   (Nepal)

^d Centers for Disease Control ^*  (United States)

^e NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COTRIMOXAZOLE; EYE OINTMENT; PENICILLIN G; SULFONAMIDE; TETRACYCLINE; TOPICAL ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM CARRIER; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NASOPHARYNX; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE; TRACHOMA;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; NASOPHARYNGEAL DISEASES; NASOPHARYNX; NEPAL; OINTMENTS; STREPTOCOCCUS PNEUMONIAE; TETRACYCLINE; TETRACYCLINE RESISTANCE; TIME FACTORS; TRACHOMA;

EID: 24044517831     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.068981     Document Type: Review

References (23)

1. Davis SD, Sarff LD, Hyndiuk RA. Corticosteroid in experimentally induced Pseudomonas keratitis: failure of prednisolone to impair the efficacy of tobramycin and carbenicillin therapy. Arch Ophthalmol 1978;96:126-8.
2. Davis SD, Sarff LD, Hyndiuk RA. Comparison of therapeutic routes in experimental pseudomonas keratitis. Am J Ophthalmol 1979;87:710-16.
3. Baum J, Barza M. Topical vs subconjunctival treatment of bacterial corneal ulcers. Ophthalmology 1983;90:162-8.
4. Leeming JP. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet 1999;37:351-60.
5. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49(Suppl 2):S79-83.
6. Krupin T, Mandell AI, Podos SM, et al. Topical corticosteroid therapy and pituitary-adrenal function. Arch Ophthalmol 1976;94:919-20.
7. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol 2002;134:749-60.
8. Thylefors B, Dawson CR, Jones BR, et al. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 1987;65:477-83.
9. Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004;363:1871-2.
10. O'Brien KL, Bronsdon MA, Dagan R, et al. Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol 2001;39:1021-4.
11. Gaynor BD, Holbrook KA, Whitcher JP, et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at one year. Br J Ophthalmol 2003;87:147-8.
12. Fry AM, Jha HC, Lietman TM, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis 2002;35:395-402.
13. Saukkoriipi A, Leskela K, Herva E, et al. Streptococcus pneumoniae in nasopharyngeal secretions of healthy children: comparison of real-time PCR and culture from STGG-transport medium. Mol Cell Probes 2004;18:147-53.
14. Stata. Stata User's Guide, Release 6. College Station, TX: Stata Press, 1999.
15. Gaynor BD, Miao Y, Cevallos V, et al. Eliminating trachoma in areas with limited disease. Emerg Infect Dis 2003;9:596-8.
16. Holm SO, Jha HC, Bhatta RC, et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Organ 2001;79:194-200.
17. Schiedler V, Bhatta RC, Miao Y, et al. Pattern of antibiotic use in a trachoma-endemic region of Nepal: implications for mass azithromycin distribution. Ophthalmic Epidemiol 2003;10:31-6.
18. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment or trachoma on carriage and resistance or Streptococcus pneumoniae. Clin Infect Dis 1997;24:356-62.
19. Chern KC, Shrestha SK, Cevallos V, et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br J Ophthalmol 1999;83:1332-5.
20. Batt SL, Charalambous BM, Solomon AW, et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2003;47:2765-9.
21. Hyde T, Gay K, Stephens D, et al. Macrolide resistance among invasive Sterptococcus pneumoniae isolates. JAMA 2001;286:1857-62.
22. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 1999;354:630-5.
23. Chidambaram JD, Bird M, Schiedler V, et al. Trachoma decline and widespread use of antimicrobial drugs. Emerg Infect Dis 2004;10:1895-9.